NEW YORK – Elios Therapeutics reported positive top-line results from a Phase IIb study involving its personalized vaccine in patients with advanced, resected melanoma.
NEW YORK – Elios Therapeutics reported positive top-line results from a Phase IIb study involving its personalized vaccine in patients with advanced, resected melanoma.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.